Targeted Genetics Corporation to Report Interim Data From a Phase I/II Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis and Highlight AAV Development Platform in 9 Additional Abstracts at ASGT Annual Meeting

SEATTLE, WA -- (MARKET WIRE) -- May 30, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) and its academic and corporate collaborators will report data in 10 oral and poster presentations, as well as Scientific and Media sessions, at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT), May 30 - June 3 in Seattle, Washington.